Remed Co

Remed Co EBIT Margin

The EBIT Margin (Operating Margin) of Remed Co (302550.KQ) as of Nov 21, 2026 is 2.96 %. In the previous year, EBIT Margin (Operating Margin) was 3.34 % — a change of -11.19% (lower).

EBIT Margin

2.96 %

YoY

-11.19%

Last updated:

EBIT Margin (Operating Margin) of Remed Co is 2025 2.96 % . EBIT Margin (Operating Margin) of Remed Co was 2024 3.34 % . It decreases by -11.19% lower compared to the previous year.

Remed Co's operating (EBIT) margin stands at 3.0%, down from 10.1% several years earlier.

The Remed Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2017
5.39 KRW
Jan 1, 2018
-10.36 KRW
Jan 1, 2019
23.24 KRW
Jan 1, 2020
10.12 KRW
Jan 1, 2021
4.72 KRW
Jan 1, 2023
6.11 KRW
Jan 1, 2024
3.34 KRW
Jan 1, 2025
2.96 KRW
The Remed Co EBIT Margin history
YEAREBIT MarginYoY
2.96 %-11.19%
3.34 %-45.40%
6.11 %+29.53%
4.72 %-53.42%
10.12 %-56.43%
23.24 %-324.36%
-10.36 %-292.08%
5.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

EBIT Margin (Operating Margin) of Remed Co is 2.96 % in 2025.

EBIT Margin (Operating Margin) of Remed Co changed from 3.34 % to 2.96 %, representing a -11.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Remed Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Remed Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Remed Co

All Key Metrics — Remed Co